Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lipocine (LPCN) has shared an update.
Lipocine Inc. has entered into a new at-the-market (ATM) agreement with A.G.P./Alliance Global Partners to offer and sell up to $10.6 million in shares. This move comes as the company terminated its previous sales agreement with Cantor Fitzgerald & Co. to facilitate this new arrangement. The shares will be sold through A.G.P. using methods allowed by law, including sales on the Nasdaq Capital Market, and A.G.P. will receive a commission of 3% on gross proceeds. Both parties retain the right to terminate the agreement with ten days’ notice, and the offering will continue only until the agreement expires or is terminated.
Learn more about LPCN stock on TipRanks’ Stock Analysis page.
